Cytotoxic drugs - Biotech, Pharma and Life Science Channel

13:52 EDT 1st April 2015 | BioPortfolio

PubMed Articles [5852 Associated PubMed Articles listed on BioPortfolio]

A mathematical model of HTLV-I infection with two time delays.

In this paper, we include two time delays in a mathematical model for the CD8+ cytotoxic T lymphocytes (CTLs) response to the Human T-cell leukaemia virus type I (HTLV-I) infection, where one is the i...

The relevance of epigenetics to occlusive cerebral and peripheral arterial disease.

Athero-thrombosis of the arteries supplying the brain and lower limb are the main causes of stroke and limb loss. New therapies are needed to improve the outcomes of athero-thrombosis. Recent evidence...

Topical NSAIDs Effect on Corneal Sensitivity.

Topical nonsteroidal antiinflammatory drugs (NSAIDs) are administered topically for a variety of ophthalmologic conditions. Brand diclofenac and brand ketorolac were previously shown to have topical a...

New Drugs 2015 Part 1.

Poly(ADP-Ribose)-A Unique Natural Polymer Structural Features, Biological Role and Approaches to the Chemical Synthesis.

Poly(ADP-ribose) (PAR) is a natural polymer, taking part in numerous important cellular processes. Several enzymes are involved in biosynthesis and degradation of PAR. One of them, poly(ADP-ribose)pol...

Chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world. Median age at diagnosis is around 70 years. To confirm the diagnosis more than 5000 B-lymphocytes/µl need ...

Alginate core-shell beads for simplified three-dimensional tumor spheroid culture and drug screening.

We demonstrate that when using cell-laden core-shell hydrogel beads to support the generation of tumor spheroids, the shell structure reduces the out-of-bead and monolayer cell proliferation that occu...

Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.

The aim of this study was to evaluate the most common adverse events (AEs) linked to everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor, in children and adolescents with tuberous scl...

Preparation of chiral quantum dots.

Chiral quantum dots (QDs) are expected to have a range of potential applications in photocatalysis, as specific antibacterial and cytotoxic drug-delivery agents, in assays, as sensors in asymmetric sy...

Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell-mediated Cytotoxicity.

Sensitivity of carcinoma cells towards gemcitabine (Gem) has been linked to mitochondrial apoptotic proteins. Recently, we described synergistic efficacy of Gem-based chemoimmunotherapy and a dendriti...

News Articles [4847 Associated News Articles listed on BioPortfolio]

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

Cancer Drugs Successfully Target Malaria Parasites

Seattle BioMed scientists use family of cancer drugs in the fight against malaria In a recent issue of Molecular Therapy, Seattle BioMed scientists Dr. Alexis Kaushansk...

Untapped cost-efficiencies are a barrier to drugs access ‘in Europe and beyond’, says WHO

A lack of collaboration and pharmacoeconomic analysis is hampering processes aimed at ensuring sustainable access to new drugs in Europe, says the World Health Organization.

In Brief: Drug Approaches Under Study for Alzheimer's

New drugs for Alzheimer's lag, but not for lack of trying -- Read more on ScientificAmerican.com

FDA To Hold Public Hearing On Homeopathy Products

Some may be surprised that the FDA is required by law to treat homeopathic remedies as drugs. But with a public hearing later this month, the agency appears poised to exercise the provisions of its au...

Oxis Biotech Discusses Its Immunotherapeutic Development Strategy

TAMPA, Fla., April 1, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] discussed during its March 31, 2015 conference call with sh...

ATyr Pharma Raises $76M Round to Advance Physocrine Drugs

The Addictions Academy Announced New Learning Platform to Target War on Drugs

Miami, FL, April 01, 2015 --(PR.com)-- The Addictions Academy announced that they are expanding learning platforms to train and educate more individuals to combat the war on drugs. With heroin and sy...

Panther Biotechnology Announces Exclusive License Agreement With Northwestern University

CHICAGO, IL -- (Marketwired) -- 04/01/15 -- Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplas...

Patheon Closes Acquisition of IRIX Pharmaceuticals

DURHAM, NC--(Marketwired - April 01, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the prev...

Events [0 Results]

None

Companies [245 Associated Companies listed on BioPortfolio]

Proteo Biotech AG

The company researches, develops and markets compounds for biological and medical research as well as for use as pharmaceuticals. The main focus is on anti-inflammatory drugs, in ...

Immune Design Corp.

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s t...

MedDay

MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executi...

Cerecor Inc.

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...

MediVector, Inc.

MediVector, Inc. is a Boston-based drug development company specializing in decreasing the time and cost of bringing drugs to market. The company complements its team’s clini...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Hydra Biosciences, Inc

Hydra Biosciences is a biopharmaceutical company developing molecular regeneration medicines, novel cardiovascular therapies and drugs targeting novel ion channels. Tapping the unharnessed power of th...

Voisin Consulting Life Sciences

Voisin Consulting assists biotechnology, pharmaceutical and biomedical companies in the design and implementation of innovative regulatory strategies to expedite product development programs such as d...

Prometheon Pharma

Prometheon Pharma is a biotechnology company housed in the globally #1-ranked Sid Martin Biotech Incubator at the University of Florida. Prometheon is dedicated to increasing pati...

ProteoTech Inc.

ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid...

Clinical Trials [339 Associated Clinical Trials listed on BioPortfolio]

Phase II Trial for Large ER-Negative Breast Cancers

A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis. Neoadjuvant treatment allows the unique opportunity to obse...

Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients

Malignant mesothelioma is an aggressive pleural disease, related to asbestos exposure. At present, cytotoxic chemotherapy is the only evidence based treatment for the disease, but efficacy...

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of response rate to conventional chemotherapy with...

Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worldwide and the third most common cause of death from cancer. Sorafenib is the only approved therapy for treatment...

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an all...

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

This study is for patients that have a type of brain cancer called glioblastoma multiforme (GBM). The body has different ways of fighting infection and disease. No single way seems perfec...

Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)

The purpose of this study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for malignant gliomas. The approach uses an adenoviral vector (disabled ...

Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours

This proof of concept study proposes targeted delivery of a broad-spectrum cytotoxic agent (doxorubicin), via a specially formulated LTSL (ThermoDox®) activated by mild hyperthermia, to a...

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.

Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)

The purpose of this study is to provide treatment with Nivolumab in combination with Ipilimumab and to assess the safety and tolerability of this combination in subjects who are anti-cytot...

Medical and Biotech [MESH] Definitions

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity.

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.

Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the United States most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Cytotoxic drugs market research data and corporate reports here

Channels Quicklinks